FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC
Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.
Related Articles
Dr Shah on the Effects of IVIG on Teclistamab-Associated Infection Risk in Myeloma
Mansi R. Shah, MD, on the effects of IVIG on infections in recipients of teclistamab therapy for multiple myeloma.
FDA Grants Breakthrough Therapy Designation to Dostarlimab for dMMR/MSI-H Rectal Cancer
Dostarlimab received breakthrough therapy designation from the FDA for locally advanced dMMR/MSI-H rectal cancer.
A Perspective on the MARS2 Trial
The phase 3 randomized controlled trial of extended pleurectomy decortication and chemotherapy versus chemotherapy alone for pleural mesothelioma (PM) (MARS2) reported “extended pleurectomy decortication was…
Bosutinib Yields Long-Term Efficacy and Safety in TKI-Pretreated CML
Treatment with bosutinib led to high response rates with a manageable safety profile in patients with CML who had previously received a TKI.
How to prevent cervical cancer before it develops
Pap tests, HPV vaccines, and cervical screenings for women January is Cervical Cancer Awareness Month, and as the new year begins, Fox Chase Cancer Center…
Clearance of driver mutations after HSCT predicts myelofibrosis relapse, survival
Patients with myelofibrosis who cleared driver mutations within 30 days after hematopoietic stem cell transplantation survived longer and exhibited reduce risk for relapse, according to…
Key Data from the CYTO-PV and MAJIC-PV Studies: Evaluating Ruxolitinib in Polycythemia Vera
Dr. Pankit Vachhani presents key data from the CYTO-PV and MAJIC-PV studies, evaluating the efficacy of ruxolitinib versus best available therapy in patients with polycythemia…
Real-World Data Shows Improved Responses for Pembrolizumab/Chemo in TNBC
A study of patients who received the KEYNOTE-522 regimen showed an improved pathologic complete response in real-world data vs what study data showed.
Mwirigi awarded HHMI fellowship for exceptional early-career scientists | WashU Medicine
Postdoctoral neuroscientist receives multiyear support for research on chronic pain
